United States· US:0002-4312_29f467c6-0365-4831-b4ce-9a0eefaf5896
Reyvow
A lasmiditan product containing lasmiditan, registered in United States by Eli Lilly and Company. The same ATC class is registered in 9 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Lasmiditan is registered in 9 of 19 countries.
Countries holding a registration under ATC N02CC08 (lasmiditan), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 6 of them publish a price we can compare per daily dose
Lasmiditan · ATC N02CC08
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- LASMIDITAN
- Manufacturer
- Eli Lilly and Company
- Country
- United States (US)
- ATC code
- N02CC08
- ATC class
- Lasmiditan
- Defined daily dose
- 0.1 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 1
- ndc110002-4312-08
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
191 interactions on record for lasmiditan.
Graded by severity as the source publishes them — 19 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lasmiditan · interactions on record
191 records
- 19 severe
- 172 moderate
Most severe, free to view
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- DolasetronA04AA04severe
- PalonosetronA04AA05severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lasmiditan in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaRAYVOWEli Lilly Nederland B.V., Utrecht
- BelgiumRayvow 100 mgEli Lilly Nederland
- FinlandRAYVOWEli Lilly Nederland B.V.
- IrelandRAYVOW 100 mg film-coated tabletsEli Lilly Nederland B.V.
- IcelandRayvowEli Lilly Nederland B.V.*
- NetherlandsRayvow 100 mg filmomhulde tablettenEli Lilly Nederland B.V.
- PolandRayvowEli Lilly Nederland B.V.
- SwedenRAYVOW 100 mg Filmdragerad tablettEli Lilly Nederland B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Rayvow
- Liechtenstein · Rayvow
- Norway · Rayvow
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/37b8d661-ba40-4dd3-aeb5-0e02e708625a GET /v1/drugs/37b8d661-ba40-4dd3-aeb5-0e02e708625a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "50",
"substance": "LASMIDITAN",
"productndc": "0002-4312",
"dosage_form": "TABLET",
"dea_schedule": "CV",
"strength_unit": "mg/1",
"application_number": "NDA211280",
"marketing_category": "NDA"
}See everything about lasmiditan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.